Samtidig administration af Tracleer 125 mg to gange dagligt i 5 dage reducerede plasmakoncentrationen af glibenclamid (et CYP3A4- substrat) med 40% med potentiel betydelig reduktion af den hypoglykæmiske virkning.
Glibenclamide: co-administration of Tracleer 125 mg twice daily for 5 days decreased the plasma concentrations of glibenclamide (a CYP3A4 substrate) by 40%, with potential significant decrease of the hypoglycaemic effect.